CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-NK 细胞中 IL-10 的耗竭增强肿瘤微环境的重编程并改善治疗效果

Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.

免疫细胞治疗有望更有效治愈髓母细胞瘤

Immune Cell Therapy Promises More Effective Cure for Medulloblastoma.

靶向 ErbB2/HER2 的 CAR-NK 细胞在重现肿瘤进展的类器官模型中清除乳腺癌细胞

ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.

CAR-NK 细胞疗法联合免疫检查点抑制在胶质母细胞瘤中诱导 NKT 细胞应答

CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.

该联合治疗逆转了免疫抑制性肿瘤微环境，T 细胞和 NKT 细胞浸润增加。

CAR-T 细胞、CAR NK 细胞和 CAR 巨噬细胞在胶质瘤模型中的不同特征及与细胞因子联合时的类似增强

CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines.

调节胶质瘤免疫微环境的治疗策略

Therapeutic approaches to modulate the immune microenvironment in gliomas.

革新胶质母细胞瘤治疗：现代治疗方法的全面概述

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

CAR-T 细胞与嵌合抗原受体 NK 细胞治疗儿童与成人高级别胶质瘤的最新进展

Chimeric Antigen Receptor T Cell and Chimeric Antigen Receptor NK Cell Therapy in Pediatric and Adult High-Grade Glioma-Recent Advances.

复发性胶质母细胞瘤患者颅内注射经 HER2 靶向嵌合抗原受体工程化的 NK 细胞

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.

颅内注射 HER2 靶向 CAR-NK 细胞在复发性 GB 患者中是可行且安全的。1 108 个 NK-92/5.28.z 细胞被确定为后续扩展队列重复局部注射 CAR-NK 细胞的最大可行剂量。

弥漫性中线胶质瘤的流行病学、诊断策略和治疗进展

Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma.